Literature DB >> 15788646

Aldosterone-producing adrenocortical carcinoma: an unusual cause of Conn's syndrome with an ominous clinical course.

Teresa M Seccia1, Ambrogio Fassina, Gastone G Nussdorfer, Achille C Pessina, Gian Paolo Rossi.   

Abstract

Aldosterone-producing adrenocortical carcinoma (APAC) is a rare cause of hypertension often diagnosed late because of paucity of information. Thus, we delineated its clinical course and survival rates based on two cases referred to us that featured diverging clinical courses, and on a scrutiny of the literature since 1955 when the first case of APAC was identified. Data on demography, imaging results, hormonal assessment, histology, and clinical course were extracted independently by the investigators. We included in our database 58 cases, most presenting with Conn's syndrome. Plasma aldosterone levels were on average increased 14-fold; plasma renin activity was suppressed in 55% of cases. The tumor showed extremely variable size and weight, and no gender or side preference. Metastases were present in 10% of all cases at initial diagnosis and in an additional 48% of cases at follow-up. Median survival was 546 days (95% confidence interval (CI): 240-851); median time to either recurrence or death was 212 days (95% CI: 29-395). No clinical or histological signs predicted survival with Cox regression analysis. We concluded that, although an ominous course with a poor survival rate is common, no sign accurately predicts the course of APAC. Thus, molecular studies to identify diagnostic markers of survival are mandatory.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15788646     DOI: 10.1677/erc.1.00867

Source DB:  PubMed          Journal:  Endocr Relat Cancer        ISSN: 1351-0088            Impact factor:   5.678


  31 in total

Review 1.  Multi-organ resection for locally advanced adrenocortical cancer: surgical strategy and literature review.

Authors:  F Guida; M Clemente; L Valvano; C Napolitano
Journal:  G Chir       Date:  2015 Sep-Oct

Review 2.  5th International ACC Symposium: Old Syndromes with New Biomarkers and New Therapies with Old Medications.

Authors:  Sarika N Rao; Mouhammed Amir Habra
Journal:  Horm Cancer       Date:  2015-12-10       Impact factor: 3.869

Review 3.  Aldosterone-secreting adrenal cortical carcinoma. A case report and review of the literature.

Authors:  Adrienne Carruth Griffin; Rachel Kelz; Virginia A LiVolsi
Journal:  Endocr Pathol       Date:  2014-09       Impact factor: 3.943

Review 4.  Management of endocrine manifestations and the use of mitotane as a chemotherapeutic agent for adrenocortical carcinoma.

Authors:  Irina Veytsman; Lynnette Nieman; Tito Fojo
Journal:  J Clin Oncol       Date:  2009-08-10       Impact factor: 44.544

5.  Management of adrenocortical carcinoma: a consensus statement of the Italian Society of Endocrinology (SIE).

Authors:  A Stigliano; I Chiodini; R Giordano; A Faggiano; L Canu; S Della Casa; P Loli; M Luconi; F Mantero; M Terzolo
Journal:  J Endocrinol Invest       Date:  2015-07-14       Impact factor: 4.256

6.  Somatic mutations in adrenocortical carcinoma with primary aldosteronism or hyperreninemic hyperaldosteronism.

Authors:  Isobel C Mouat; Kei Omata; Andrew S McDaniel; Namita G Hattangady; Debnita Talapatra; Andi K Cani; Daniel H Hovelson; Scott A Tomlins; William E Rainey; Gary D Hammer; Thomas J Giordano; Tobias Else
Journal:  Endocr Relat Cancer       Date:  2019-02       Impact factor: 5.678

Review 7.  Surgical management of adrenocortical tumours.

Authors:  Barbra S Miller; Gerard M Doherty
Journal:  Nat Rev Endocrinol       Date:  2014-03-18       Impact factor: 43.330

Review 8.  Adrenocortical carcinoma.

Authors:  Tobias Else; Alex C Kim; Aaron Sabolch; Victoria M Raymond; Asha Kandathil; Elaine M Caoili; Shruti Jolly; Barbra S Miller; Thomas J Giordano; Gary D Hammer
Journal:  Endocr Rev       Date:  2013-12-20       Impact factor: 19.871

Review 9.  A comprehensive review of the clinical aspects of primary aldosteronism.

Authors:  Gian Paolo Rossi
Journal:  Nat Rev Endocrinol       Date:  2011-05-24       Impact factor: 43.330

10.  Predictors of malignancy in primary aldosteronism.

Authors:  Ayman Agha; Matthias Hornung; Igors Iesalnieks; Andreas Schreyer; Ernst Michael Jung; Assad Haneya; Hans J Schlitt
Journal:  Langenbecks Arch Surg       Date:  2013-09-19       Impact factor: 3.445

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.